Download Scientific Materials

[POSTER] Development and Validation of Blood Tumor Mutational Burden Reference Standards We announced the availability of a range of human diseased cell line based Seraseq® Blood TMB (bTMB) reference controls to support the validation and precise measurements of plasma-derived blood tumor mutational burden by targeted ccfDNA NGS assays. This poster describes the development and validation of blood tumor mutational burden reference standards, and was presented at the 35th Meeting of the Society for Immunotherapy in Cancer (SITC 2020).

[POSTER] Reference Materials for Measurable Residual Disease (MRD) Monitoring in Circulating Cell-Free DNA
Presented at AMP 2020, this poster describes RMs for the development, validation, and control of MRD assays. We designed our RMs for a tumor/normal MRD workflow as a set of three components based on our Tumor Mutational Burden (TMB) and blood TMB (bTMB) reference materials.

[VIDEO] The Promise of Liquid Biopsy Application to Cancer Disease Diagnostics and Therapeutic Monitoring
Circulating cell free DNA as a surrogate sample type for effective diagnostics has remained an area of significant interest. ctDNA has been demonstrated to mirror the tumor mutational landscape and has the potential to monitor mutational changes from therapy over time. This webinar brings together academic, clinical and industry experts in the ctDNA field describing the promises and challenges of liquid biopsy in disease management.

[POSTER] Development of Reference Material for Blood Tumor Mutational Burden Measurement
Although most TMB measurements are made from genomic DNA that has been extracted from formalin-fixed paraffin embedded tissue sections, some diagnostic tests attempt to measure TMB in circulating tumor DNA (ctDNA) extracted from blood samples; an approach referred to as blood TMB (bTMB). bTMB is an attractive biomarker since it has the potential to bypass many of the obstacles encountered with resected and hard to biopsy tumors. This poster shows how we developed our reference material for blood tumor mutational burden measurement.